We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Breakthrough Polymer Significantly Improves Safety of Implantable Medical Devices

By HospiMedica International staff writers
Posted on 02 Jul 2025

Every year, millions of patients receive implantable cardiovascular devices such as arterial and venous catheters, pacemaker leads, artificial hearts, and vascular prostheses. More...

These devices, typically made from polyurethane (PU), are essential for life-saving interventions but present several problems. PU production relies on toxic isocyanates and has been linked to serious complications, including blood clots and infections. These materials can trigger platelet adhesion, coagulation, and bacterial contamination—especially from staphylococcus aureus—raising the risk of implant failure and adverse reactions. To address these limitations, researchers have developed a safer, more biocompatible, and environmentally friendly alternative that could replace PU in many medical applications.

A scientific team from the Université de Liège (Liège, Belgium) has developed an innovative polymer called PHOx (Poly Hydroxy-Oxazolidone), a non-isocyanate polyurethane (NIPU) elastomer designed for implantable medical devices. This invention is the subject of an international patent application. PHOx is a flexible, thermoplastic material that can be molded, pressed, spun into fibers, or even 3D printed. Its formulation is based on greener raw materials, including carbon dioxide, making the production process significantly less harmful to the environment. The design of PHOx aims to replicate the mechanical flexibility of PU while eliminating its toxic by-products. Because it can be easily shaped and 3D printed, PHOx is suitable for custom manufacturing of personalized devices tailored to each patient's anatomy, such as heart valves and vascular implants, reducing waste and production costs.

Extensive laboratory tests demonstrated PHOx’s superiority over PU in several performance areas. In findings published in the scientific journal Advanced Healthcare Materials, the new material showed more than 90% cell survival and no toxicity to human cells. It significantly reduced platelet adhesion and coagulation activation, thereby lowering the risk of blood clot formation. It also inhibited bacterial adhesion, reducing the chances of infection. Importantly, it did not provoke inflammation, degradation, or rejection after implantation. Thanks to its porous structure and stability, PHOx supports long-term integration in the body. Researchers believe this is the first time a NIPU material has achieved such promising results in critical medical settings. With further validation, PHOx could be widely adopted for safer, greener, and more economical medical device production, replacing PU in many clinical applications.

Related Links:
Université de Liège


Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Endoscopy Display
E190
New
High-Precision QA Tool
DEXA Phantom
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.